Network pharmacology target cluster (MMP9, VEGFA, EGF, AKT1, CASP3, ESR1, DRD2, GSK3B)

This entry represents a heterogeneous collection of key protein nodes frequently identified in network pharmacology studies as central hubs for multi-target drug action. These nodes include enzymes like Matrix metalloproteinase-9 (MMP9) and Caspase-3 (CASP3), growth factors such as Vascular endothelial growth factor A (VEGFA) and Epidermal growth factor (EGF), kinases like AKT1 and GSK3B, and receptors including Estrogen receptor alpha (ESR1) and Dopamine receptor D2 (DRD2). Collectively, they regulate fundamental biological processes such as cell proliferation, apoptosis, angiogenesis, and signal transduction across various tissues (UniProt P14780, P15692, P31749). In disease states, these proteins are often dysregulated, contributing to the progression of cancer, cardiovascular diseases, and neurodegenerative disorders (Hopkins, 2008, Nature Chemical Biology). Because these molecules are highly interconnected within biological networks, they are often analyzed together to understand the synergistic effects of complex therapeutic interventions, such as traditional medicines or multi-kinase inhibitors. Targeting this specific cluster allows researchers to evaluate how a single drug or a combination of compounds can modulate multiple pathways simultaneously to achieve a therapeutic effect. However, as a single target entity, this list is considered incorrect for standard drug-target registration due to the inclusion of multiple distinct proteins with diverse molecular functions. Pharmacological intervention across these nodes requires careful calibration to avoid systemic toxicity while maintaining therapeutic efficacy (NIH, National Cancer Institute).

Other names

Matrix metalloproteinase-9 (MMP9)Vascular endothelial growth factor A (VEGFA)Epidermal growth factor (EGF)RAC-alpha serine/threonine-protein kinase (AKT1)Caspase-3 (CASP3)Estrogen receptor alpha (ESR1)Dopamine receptor D2 (DRD2)Glycogen synthase kinase-3 beta (GSK3B)

Multi-target modulation involving the inhibition of proteolytic activity, antagonism of growth factor signaling, inhibition of protein kinases, modulation of nuclear receptor transcription, and antagonism of G-protein coupled receptors.